Biomarkers in Chronic Obstructive Pulmonary Disease: The Gateway to Precision Medicine.

Abstract

Chronic obstructive pulmonary disease (COPD) is a highly heterogeneous disease with limited adequate treatments. Biomarkers-which may relate to disease susceptibility, diagnosis, prognosis, or treatment response-are ideally suited to dissecting such a complex disease and form a critical component of the precision medicine paradigm. Not all potential candidates, however, make good biomarkers. To date, only plasma fibrinogen has been approved by regulatory bodies as a biomarker of exacerbation risk for clinical trial enrichment. This review outlines some of the challenges of biomarker research in COPD and highlights novel and promising biomarker candidates.

• Authors: Stephen Milne, Don D Sin
• Journal: Clinics in chest medicine (Clin Chest Med) Vol. 41 Issue 3 Pg. 383-394 (09 2020) ISSN: 1557-8216 [Electronic] United States
• PMID: 32800193 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020 Elsevier Inc. All rights reserved.

Chemical References

• Biomarkers

Topics

• Biomarkers (blood)
• Humans
• Precision Medicine (methods)
• Pulmonary Disease, Chronic Obstructive (diagnosis)